• Home
  • Protein Characterization
    • Protein Quantification
      • Amino Acid Analysis (AAA)
      • Extinction Coefficient (A280)
    • Protein Primary Structure
      • Peptide Mapping
      • De-Novo Sequencing
      • Intact Mass
      • N/C-Terminal Sequencing
      • Disulfide Linkage
    • Glycosylation
      • N-linked Glycosylation
      • O-linked Glycosylation
      • Sialic Acid Content
      • Monosaccharide Analysis
      • Glycosylation Site
    • Protein Modification
      • Deamidation
      • Oxidation
      • Other Modifications
    • Bioassay
      • ELISA
      • Cell-based Assays
    • Protein Impurities
      • Process- and Product-Related Impurities
      • Proteases activity
  • Biopharmaceuticals
    • Antibody Characterization
    • Antibody Drug Conjugates
    • Comparability
    • Stability
    • Release Testing
    • GMP Protein Analysis
    • ICH Q6B
    • Host Cell Proteins
    • Services provided by Charles River BPS
  • Biosimilars
    • Abatacept
    • Adalimumab
    • Bevacizumab
    • Cetuximab
    • Denosumab
    • Eculizumab
    • Erythropoietin
    • Etanercept
    • Factor VIII
    • G-CSF
    • Golimumab
    • Infliximab
    • Ipilimumab
    • Natalizumab
    • Ranibizumab
    • Rituximab
    • Tocilizumab
    • Trastuzumab
    • Ustekinumab
  • Methods
    • Mass Spectrometry
      • LC-ESI-MS/MS
      • MALDI-MS/MS
      • MALDI-ISD
    • Bioinformatics
    • Liquid Chromatography
    • Electrophoresis
    • List of Instrumentation
  • Company
    • Quality
    • News & Press
      • News
      • Press Releases
      • Newsletter
    • Events
      • Events Archive
    • Management
    • Partners and Network
    • Career
      • Job Opportunities
      • Unsolicited Application
      • Working at Protagen Protein Services
    • Downloads
      • Information & Brochures
      • Publications
        • Protein Services
        • Bio-IT
    • Contact
      • Contact Details
      • Disclaimer
      • Terms & Conditions
  • Imprint
    • Imprint Details
    • Data Protection Statement

10th PEGS Europe

Protein & Antibody Engineering Summit

 

12. - 16. November 2018

Lisbon Congress Center, Lisbon, Portugal

 

https://www.pegsummiteurope.com/

 

To arrange a meeting contact us and find out more about the competencies of Protagen Protein Services (PPS)

 

  • Home
  • Protein Characterization
  • Biopharmaceuticals
  • Biosimilars
  • Methods
  • Company
    • Quality
    • News & Press
    • Events
      • Events Archive
    • Management
    • Partners and Network
    • Career
    • Downloads
    • Contact
  • Imprint

Protein Characterization

Biopharmaceuticals

Biosimilars

 Biosimilars

Analytical Methods

Company

  • Protein Quantification
  • Protein Primary Structure
  • Glycosylation
  • Protein Modification
  • Bioassay
  • Protein Impurities
  • Antibodies
  • Antibody Drug Conjugates
  • Comparability
  • Stability
  • Release Testing
  • GMP Protein Analysis
  • ICH Q6B
  • Host Cell Proteins
  • Biosimilars
  • Abatacept
  • Adalimumab
  • Bevacizumab
  • Cetuximab
  • Denosumab
  • Eculizumab
  • Erythropoietin
  • Etanercept
  • Factor VIII
  • G-CSF
  • Golimumab
  • Infliximab
  • Ipilimumab
  • Natalizumab
  • Ranibizumab
  • Rituximab
  • Tocilizumab
  • Trastuzumab
  • Ustekinumab
  • Mass Spectrometry
  • Bio-IT in Mass Spectrometry
  • Liquid Chromatography
  • Electrophoresis
  • List of instrumentation
  • News & Press
  • Events
  • Management
  • Partners and Network
  • Career
  • Contact
© 1997-2019 Protagen Protein Services GmbH | Germany | +49 231 9742 6100 | contact@ProtagenProteinServices.com
Court Stuttgart HRB: 382627| VAT DE814132039